Advertisement
Canada markets close in 5 hours 34 minutes
  • S&P/TSX

    21,949.72
    +64.34 (+0.29%)
     
  • S&P 500

    5,102.77
    +54.35 (+1.08%)
     
  • DOW

    38,279.24
    +193.44 (+0.51%)
     
  • CAD/USD

    0.7321
    -0.0003 (-0.03%)
     
  • CRUDE OIL

    84.03
    +0.46 (+0.55%)
     
  • Bitcoin CAD

    88,239.95
    +1,179.72 (+1.36%)
     
  • CMC Crypto 200

    1,338.67
    -57.87 (-4.01%)
     
  • GOLD FUTURES

    2,352.10
    +9.60 (+0.41%)
     
  • RUSSELL 2000

    2,002.08
    +20.97 (+1.06%)
     
  • 10-Yr Bond

    4.6550
    -0.0510 (-1.08%)
     
  • NASDAQ

    15,916.67
    +304.91 (+1.95%)
     
  • VOLATILITY

    15.24
    -0.13 (-0.85%)
     
  • FTSE

    8,136.00
    +57.14 (+0.71%)
     
  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     
  • CAD/EUR

    0.6841
    +0.0020 (+0.29%)
     

Apple grows, Kohl's stalls and Puma Biotech tumbles

Time for your daily dose of trending tickers, the stocks you're following based on your Yahoo Finance ticker searches.

Apple

The worlds largest company by market cap just got a little bigger. Shares of Apple (AAPL) popped 1% on Thursday after UBS said iPhone sales should continue to smash records. In a new research note, analysts said in the second quarter Apple will sell about 51 million units, that's much more than the consensus Street estimates of 45 million. UBS cited strong demand in China as one of the catalysts behind the gains.

Kohl’s

'No sale' for Kohl's (KSS). Investors sent shares 11% lower after Kohl's missed same-store sales for the first quarter. The department store giant blamed the cold winter for sales rising just 1.4%, which was much less than analysts' expectations of 2.6%.

ADVERTISEMENT

Get the Latest Market Data and News with the Yahoo Finance App

Puma Biotech

Shares of Puma Biotech (PBYI) are running but in the wrong direction. The stock tumbled nearly 20% today after lackluster drug results sent investors running for cover. Specifically, research showed that although one of its new drugs suppressed breast cancer, it didn’t suppress it for all that long – less than 3 months. As is so often the case with drug developers, their stocks rise and fall based on treatments in the pipeline.

More from Yahoo Finance

Despite record $180M Picasso, art market no bubble

Small changes that boost 401k by $300K

In a slow-growth economy, pay up for growth stocks